MetrioPharm AG, MetrioPharm Deutschland GmbH – Patent Protection

en
de

Home
About us
Technology
Pipeline
- Indications
- Patent Protection
Investors
Press
- Press Releases
- Corporate Calendar
Contact
en
de

Home
Pipeline
Patent Protection

News

Press Release: Prof. Dr. Marcus Thelen Joins MetrioPharm AG as Chief Scientific Officer (CSO) - 2025-Sep-12

Prof. Dr. Marcus Thelen has been appointed Chief Scientific Officer (CSO) and will strengthen MetrioPharm’s scientific development strategy.

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact

Social

Press Releases

Subscribe to our press releases with the
MetrioPharm PR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Germany (R&D)

MetrioPharm Deutschland GmbH

Franklinstrasse 28/29
10587 Berlin

© 2026 MetrioPharm AG
Imprint
Privacy policy (We don’t collect cookies)
Sitemap